Patients on Enjaymo show immune response to COVID-19 vaccines
People with cold agglutinin disease (CAD) who were on Enjaymo (sutimlimab-jome) during clinical trials produced antibodies in response to COVID-19 vaccination, suggesting their ability to mount an immune response was not impaired, a recent study reports. In patients with a waning immune response, a booster dose was enough…